Integrase inhibitors - PDFSEARCH.IO - Document Search Engine

Integrase inhibitors
Results: 73

#	Item
1	June 17, 2009 Chemicals Targeting an HIV‐1 Nef/Host Cell Kinase Complex as Novel Anti‐ Retroviral Compounds Damilola A. Adepegba, Department of Natural Sciences, University of Maryland Add to Reading List Source URL: www.csb.pitt.edu Language: English - Date: 2013-11-27 16:23:21 Microbiology HIV/AIDS Virology Integrase HIV Nef Management of HIV/AIDS Zidovudine Retrovirus Discovery and development of integrase inhibitors Discovery and development of HIV-protease inhibitors
2	GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a reasonable testing program, the product referenced in this certificate complies with applicable regulations Add to Reading List Source URL: gilead.com Language: English - Date: 2013-02-24 19:40:20 Organofluorides Pharmacology Integrase inhibitors Tenofovir Emtricitabine Gilead Cobicistat Elvitegravir GS Gilead Sciences Chemistry Organic chemistry
3	Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:24 Intel Viiv Integrase inhibitors Organofluorides Pfizer Biology Pharmacology Dolutegravir Shionogi Pharmaceutical industry Pharmaceutical sciences ViiV Healthcare GlaxoSmithKline
4	Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:22 Medicine HIV/AIDS Cyclopropanes Integrase inhibitors Amides Lamivudine Zidovudine Antiretroviral drug GlaxoSmithKline Chemistry Organic chemistry Organofluorides
5	Once‐Daily Dolutegravir is Non‐Inferior to Twice‐Daily Raltegravir in Treatment‐Naïve Adults with HIV‐1  Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:21 Organic chemistry Health HIV/AIDS Amides Oxadiazoles Raltegravir Lamivudine GlaxoSmithKline Dolutegravir Organofluorides Chemistry Integrase inhibitors
6	Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:11 Sulfonamides Medicine Carbamates Darunavir HIV/AIDS Antiretroviral drug ViiV Healthcare Zidovudine Integrase inhibitor Protease inhibitors Chemistry Biology
7	Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:24 Organic chemistry Medicine Amides Merck Oxadiazoles Raltegravir Integrase Dolutegravir ViiV Healthcare Integrase inhibitors Chemistry Organofluorides
8	ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2015-01-27 14:49:56 Integrase inhibitors Abacavir Cyclopropanes Purines Antiretroviral drug HIV/AIDS Lamivudine Reverse-transcriptase inhibitor ViiV Healthcare Biology Chemistry Organofluorides
9	Microsoft Word - 20130218_FDA Priority Review Designation for DTG_E_Final Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:24 Pharmacology Integrase inhibitors HIV/AIDS Intel Viiv Shionogi ViiV Healthcare Integrase New Drug Application Prescription Drug User Fee Act Food and Drug Administration Pharmaceutical sciences Medicine
10	Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor Phase III Treatment-naïve and Treatment-experienced Trials Underway for S/GSK1349572 (‘572) Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:21 Health Medicine Integrase inhibitors GlaxoSmithKline ViiV Healthcare Lamivudine Pfizer Integrase Raltegravir Organofluorides Chemistry HIV/AIDS